LBRX · Insider Trading
LB Pharmaceuticals Inc Common Stock
Every open-market purchase and sale reported by LBRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Susan Gani Kozauer | Chief Medical Officer | A | +200,000 deriv. | — |
| 2026-10-13 | Joseph M Miller | Chief Financial Officer | A | +200,000 deriv. | — |
| 2026-08-03 | Deep Track Biotechnology Master Fund, Ltd. | 10%+ Owner | Buy | +858,615 deriv. | — |
| 2026-06-05 | Rebecca Luse | Director | A | +10,000 deriv. | — |
| 2026-06-05 | Rekha Hemrajani | Director | A | +10,000 deriv. | — |
| 2026-06-05 | Robert R Ruffolo | Director | A | +10,000 deriv. | — |
| 2026-06-05 | Robert A. Lenz | Director | A | +12,500 deriv. | — |
| 2026-06-05 | William P Kane Jr | Director | A | +10,000 deriv. | — |
| 2026-06-05 | J. Scott Garland | Director | A | +10,000 deriv. | — |
| 2026-06-05 | Ran Nussbaum | Director | A | +10,000 deriv. | — |
| 2026-03-10 | Robert A. Lenz | Director | A | +20,000 deriv. | — |
| 2026-02-10 | Deep Track Special Opportunities Fund, LP | 10%+ Owner | Buy | +1,889,476 deriv. | — |
| 2025-12-11 | Panandiker Kaya Kamlesh Pai | Chief Commercial Officer | A | +195,000 deriv. | — |
| 2025-09-29 | Marc L Panoff | Senior Vice President, Finance | MIXED | +90,525 deriv. | — |
| 2025-09-16 | Pontifax Management 4 G.P. (2015) Ltd. | 10%+ Owner | MIXED | +1,411,681 | +$15.00M |
| 2025-09-16 | Ran Nussbaum | Director | MIXED | +1,411,681 | +$15.00M |
| 2025-09-16 | Deep Track Biotechnology Master Fund, Ltd. | 10%+ Owner | MIXED | +10,058,412 | +$120.00M |
| 2025-09-16 | Vida Ventures GP III, L.L.C. | 10%+ Owner | MIXED | +4,411,215 | +$25.00M |
| 2025-09-12 | Rekha Hemrajani | Director | A | +22,449 deriv. | — |
| 2025-09-12 | William P Kane Jr | Director | A | +22,449 deriv. | — |
| 2025-09-12 | Ran Nussbaum | Director | A | +22,449 deriv. | — |
| 2025-09-12 | Rebecca Luse | Director | A | +22,449 deriv. | — |
| 2025-09-12 | Anna Eramo | Chief Medical Officer | MIXED | +155,812 deriv. | — |
| 2025-09-12 | J. Scott Garland | Director | MIXED | +22,449 deriv. | — |
| 2025-09-12 | Heather D Turner | Chief Executive Officer | MIXED | +971,828 deriv. | — |
| 2025-09-12 | Richard Anthony Silva | SVP, Technical Operations | MIXED | +80,899 deriv. | — |
| 2025-09-12 | Zachary Prensky | Director | MIXED | +22,449 deriv. | — |
| 2025-09-12 | Robert R Ruffolo | Director | MIXED | +22,449 deriv. | — |
| 2025-09-12 | Gad Soffer | Chief Business Officer | MIXED | +229,860 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd. | 10%+ Owner | 3,352,804 | $131.90M |
| Ran Nussbaum | Director | 1,411,681 | $55.54M |
| Pontifax Management 4 G.P. (2015) Ltd. | 10%+ Owner | 1,411,681 | $55.54M |
| Vida Ventures GP III, L.L.C. | 10%+ Owner | 1,434 | $56.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LBRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.